Cognito Therapeutics Announces Scientific Presentations at the Alzheimer’s Association International Conference 2024
July 08 2024 - 7:00AM
Business Wire
Cognito Therapeutics, a leader in technology-based therapeutic
interventions for neurodegenerative diseases, today announced that
it will present four scientific posters at the Alzheimer’s
Association International Conference 2024 (AAIC). The largest
international meeting dedicated to advancing dementia science, AAIC
will be held in Philadelphia, PA, and online from July 28 – Aug 1,
2024.
“We are excited to share our latest data demonstrating the
potential of our non-invasive neuromodulation therapy to slow
Alzheimer’s disease progression and result in time saved,” said
Ralph Kern, M.D. MHSc, Chief Medical Officer, Cognito Therapeutics.
“By modifying synaptic and myelin proteins and reducing white
matter and brain volume loss, our disease-modifying therapy may
play a key role in maintaining brain function. We look forward to
presenting our latest clinical research findings and their
implications for future treatments with the global Alzheimer's
research community at AAIC 2024.”
Details of the presentations are as follows:
OVERTURE I Phase 2 Study time-savings analysis using
composite measures of function and cognition Date/Time: Sunday,
July 28, 2024: 8:00 AM – 4:15 PM ET Presenting Author: Ralph Kern,
M.D. MHSc, Chief Medical Officer, Cognito Therapeutics Poster
Number: 94669 Session: Developing Topics: Drug Development
OVERTURE I Phase 2 Clinical Trial MRI Outcomes Demonstrate
Consistent Treatment Benefits in Subgroup Analysis Date/Time:
Tuesday, July 30, 2024: 7:30 AM – 4:15 PM EDT Presenting Author:
Lily Lee PhD, Vice President and Head of Medical Affairs, Cognito
Therapeutics Poster Number: 85091 Session: Biomarkers:
Neuroimaging
Mechanistic Insights of Gamma Sensory Stimulation: CSF
Proteomic Analyses Reveal Changes in Myelin and Synaptic
Proteins Date/Time: Tuesday, July 30, 2024: 7:30 AM – 4:15 PM
ET Presenting Author: Mihaly Hajos PhD, Chief Scientific Officer,
Cognito Therapeutics Poster Number: 87390 Session: Biomarkers:
Biomarkers (non-neuroimaging)
OVERTURE I Phase 2 MRI Analysis Demonstrates Reduced Corpus
Callosum Atrophy in Alzheimer's Disease Date/Time: Wednesday,
July 31, 2024: 7:30 AM – 4:15 PM Presenting Author: Ralph Kern,
M.D. MHSc, Chief Medical Officer, Cognito Therapeutics Poster
Number: 85446 Session: Biomarkers: Neuroimaging
To meet with the Cognito team on-site at AAIC, please contact
aaic2024@cognitotx.com.
About Cognito Therapeutics
Cognito Therapeutics is a late clinical-stage neurotechnology
company dedicated to the development of transformative
disease-modifying therapies for neurodegenerative diseases.
Cognito’s proprietary approach targets dysregulated network
activity in the brain and has shown meaningful outcomes in
Alzheimer’s patients. Cognito’s lead product, Spectris, employs a
proprietary non-invasive method designed to evoke increased gamma
frequency brain activity using auditory and visual neuromodulation
to slow the rate of brain atrophy and loss of brain function.
Cognito’s mission is to develop a new class of technology-based
therapeutic interventions to transform the lives of patients with
neurodegenerative diseases. Cognito is headquartered in Cambridge,
MA. For more information, visit www.cognitotx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240708403475/en/
Kimberly Ha KKH Advisors 917-291-5744
kimberly.ha@kkhadvisors.com